Publications dans lesquelles il/elle collabore avec MARÍA VICTORIA CALVO HERNÁNDEZ (17)

2022

  1. Physiologically-based pharmacokinetic modelling and dosing evaluation of gentamicin in neonates using PhysPK

    Frontiers in Pharmacology, Vol. 13

2021

  1. Evaluation of current amikacin dosing recommendations and development of an interactive nomogram: The role of albumin

    Pharmaceutics, Vol. 13, Núm. 2, pp. 1-13

2020

  1. Amikacin initial dosage in patients with hypoalbuminaemia: an interactive tool based on a population pharmacokinetic approach

    The Journal of antimicrobial chemotherapy, Vol. 75, Núm. 8, pp. 2222-2231

2019

  1. Evaluation of renal function equations to predict amikacin clearance

    Expert Review of Clinical Pharmacology, Vol. 12, Núm. 8, pp. 805-813

2017

  1. Pharmacokinetics and dosing requirements of digoxin in pregnant women treated for fetal supraventricular tachycardia

    Expert Review of Clinical Pharmacology, Vol. 10, Núm. 8, pp. 911-917

2009

  1. Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients

    Journal of Pharmacy and Pharmacology, Vol. 61, Núm. 6, pp. 759-766

2008

  1. Recomendaciones para la monitorización de antibióticos en pacientes críticos ingresados en UCI

    Enfermedades Infecciosas y Microbiologia Clinica

  2. Recommendations for antibiotic monitoring in ICU patients

    Farmacia Hospitalaria

2005

  1. Time-dependent pharmacokinetics of cyclosporine (Neoral®) in de novo renal transplant patients

    Journal of Clinical Pharmacy and Therapeutics, Vol. 30, Núm. 6, pp. 549-557

2004

  1. Pharmacokinetic basis for the use of extended interval dosage regimens of gentamicin in neonates

    Journal of Antimicrobial Chemotherapy, Vol. 54, Núm. 1, pp. 193-198

1999

  1. Population pharmacokinetics of amikacin in patients with haematological malignancies

    Journal of Antimicrobial Chemotherapy, Vol. 44, Núm. 2, pp. 235-242

1996

  1. Influence of pharmacokinetic model on vancomycin peak concentration targets

    Therapeutic Drug Monitoring, Vol. 18, Núm. 2, pp. 145-148

  2. Pharmacokinetics of amikacin in intensive care unit patients

    Journal of Clinical Pharmacy and Therapeutics, Vol. 21, Núm. 6, pp. 417-421

1993

  1. Digoxin pharmacokinetics in patients with high serum digoxin concentrations

    Journal of Clinical Pharmacy and Therapeutics, Vol. 18, Núm. 1, pp. 63-68

1989

  1. POPULATION PHARMACOKINETIC STUDY OF GENTAMICIN AND A BAYESIAN APPROACH IN PATIENTS WITH RENAL IMPAIRMENT

    Journal of Clinical Pharmacy and Therapeutics, Vol. 14, Núm. 3, pp. 213-223

1987

  1. Bioavailability of rectally administered naproxen

    International Journal of Pharmaceutics, Vol. 38, Núm. 1-3, pp. 117-122

1985

  1. Pharmacokinetics and initial distribution of a new neuroleptic agent picobenzide (M-14012-4)

    International Journal of Clinical Pharmacology Therapy and Toxicology, Vol. 23, Núm. 5, pp. 233-237